(Total Views: 615)
Posted On: 09/11/2025 2:23:59 AM
Post# of 156894
As much as I wish it weren't so, here's a copy of the section of the ESMO CRC poster from the upper right corner titled: Ongoing studies with Leronlimab in CRC
"Patients completing study CD-O-101 will be given the option to enter a roll-
over study where they can continue to receive leronlimab. Patients who
have progressed on the parent study will also be offered treatment with
leronlimab in combination with an immune checkpoint inhibitor."
Note that it says "Patients completing study". To me that means ICI's only after completion of the full 48 weeks.
"Patients completing study CD-O-101 will be given the option to enter a roll-
over study where they can continue to receive leronlimab. Patients who
have progressed on the parent study will also be offered treatment with
leronlimab in combination with an immune checkpoint inhibitor."
Note that it says "Patients completing study". To me that means ICI's only after completion of the full 48 weeks.
(6)
(0)
